Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $46.09 Consensus PT from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $46.0909.

CAPR has been the topic of a number of recent research reports. Oppenheimer boosted their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. iA Financial set a $48.00 target price on Capricor Therapeutics in a research note on Wednesday, December 3rd. UBS Group set a $50.00 price target on Capricor Therapeutics in a report on Monday, December 15th. Maxim Group boosted their price target on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday, December 3rd.

Institutional Trading of Capricor Therapeutics

Several hedge funds have recently made changes to their positions in the company. Suvretta Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth approximately $51,533,000. Tang Capital Management LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at approximately $49,062,000. RA Capital Management L.P. acquired a new position in Capricor Therapeutics in the fourth quarter valued at approximately $43,516,000. Darwin Global Management Ltd. purchased a new position in Capricor Therapeutics in the fourth quarter worth approximately $23,168,000. Finally, SB Capital Management Inc purchased a new position in Capricor Therapeutics in the fourth quarter worth approximately $11,544,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Up 3.4%

CAPR stock opened at $30.10 on Friday. The firm has a 50-day moving average of $26.34 and a two-hundred day moving average of $17.69. Capricor Therapeutics has a 12 month low of $4.30 and a 12 month high of $40.37. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -13.32 and a beta of 0.37.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, equities analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.